830346-51-5

Basic information

• Product Name: tert-butyl N-[(1R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxo-pyrimidin-1-yl]-1-phenyl-ethyl]carbamate
• Synonyms: Elagolix Impurity 9;Elagolix Impurity 20;N-Boc Desbutyrate Elagolix;tert-butyl N-[(1R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-[[2-fl...;TERT-BUTYL (R)-(2-(5-(2-FLUORO-3-METHOXYPHENYL)-3-(2-FLUORO-6-(TRIFLUOROMETHYL)BENZYL)-4-METHYL-2,6-;(R)-3-[2-(Boc-amino)-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4(1H,3H)-dione;3-[(2R)-N-(tert-butoxycarbonyl)amino-2-phenylethyl]-2-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-2,4(1H,3H)-pyrimidinedione;tert-butyl N-[(1R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxo-pyrimidin-1-yl]-1-phenyl-ethyl]carbamate;tert-butyl (R)-(2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-3,6-dihydropyrimidin-1(2H)-yl)-1-phenylethyl)carbamate;(R)-tert-butyl (2-(5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-(trifluoromethyl)benzyl)-4-methyl-2,6-dioxo-2,3-dihydropyrimidin-1(6H)-yl)-1-phenylethyl)carbamate
• CAS NO: 830346-51-5
• Molecular Formula: C₃₃H₃₂F₅N₃O₅
• Molecular Weight: 645.6163
• Mol File: 830346-51-5.mol

Chemical Properties

• Density: 1.309g/cm³
• Refractive Index: 1.553
• Storage Temp.: -20°C Freezer
• Solubility: Dichloromethane; Methanol
• PKA: 11.50±0.46(Predicted)
• CAS DataBase Reference: tert-butyl N-[(1R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxo-pyrimidin-1-yl]-1-phenyl-ethyl]carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: tert-butyl N-[(1R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxo-pyrimidin-1-yl]-1-phenyl-ethyl]carbamate(830346-51-5)
• EPA Substance Registry System: tert-butyl N-[(1R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxo-pyrimidin-1-yl]-1-phenyl-ethyl]carbamate(830346-51-5)

Safety Data

• Hazardous Substances Data: 830346-51-5(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
tert-butyl N-[(1R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxo-pyrimidin-1-yl]-1-phenyl-ethyl]carbamate is used as an intermediate in the synthesis of Elagolix-d6 Sodium Salt (E501016), a labelled analogue of Elagolix Sodium Salt (E501018). Elagolix Sodium Salt is a novel uracil phenylethylamine that acts as a potent human gonadotropin-releasing hormone receptor (hGnRH-R) antagonist. This antagonistic activity makes it a potential candidate for the treatment of various hormonal disorders and conditions related to the gonadotropin-releasing hormone system.
Used in Research and Development:
Due to its unique structure and potential biological activity, tert-butyl N-[(1R)-2-[5-(2-fluoro-3-methoxy-phenyl)-3-[[2-fluoro-6-(trifluoromethyl)phenyl]methyl]-4-methyl-2,6-dioxo-pyrimidin-1-yl]-1-phenyl-ethyl]carbamate may also be used in research and development for the discovery of new drugs and therapeutic agents. Its synthesis and modification can provide valuable insights into the structure-activity relationships of hGnRH-R antagonists and other related compounds, potentially leading to the development of more effective and targeted treatments for various medical conditions.

Upstream product

• 1150560-59-0 5-(2-fluoro-3-methoxyphenyl)-1-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}-6-methylpyrimidine-2,4(1H,3H)-dione 
• 126610-77-3 (R)-tert-butyl N-<1-phenyl-2-<(p-toluenesulfonyl)oxy>ethyl>carbamate 
• 102089-75-8 (-)-(1R)-1-[(1',1'-dimethylethoxycarbonyl)amino]-2-(methylsulfonyl)oxy-1-phenylethane 
• 830346-48-0 5-bromo-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methylpyrimidine-2,4-(1H,3H)-dione 
• 830346-46-8 N-{[2-fluoro-6-(trifluoromethyl)phenyl]methyl}urea 
• 239087-06-0 (2-fluoro-6-(trifluoromethyl) phenyl)methanamine 
• 295376-21-5 2-fluoro-3-methoxy-1-bromobenzene 
• 1080673-30-8 2-fluoro-1-iodo-3-methoxybenzene 
• 67341-01-9 (R)-N-(tert-butoxycarbonyl)phenylglycinol 
• 137102-65-9 (R)-(2-amino-1-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 134364-69-5 2.3-difluoroanisole 
• 830346-47-9 1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-2,4(1H,3H)-pyrimidinedione 
• 352303-67-4 (2-fluoro-3-methoxyphenyl)boronic acid 
• 15018-56-1 5-bromo-6-methyluracil 

Downstream Products

• 832720-84-0 4-((R)-2-[5-(2-fluoro-3-methoxyphenyl)-3-(2-fluoro-6-trifluoromethylbenzyl)-4-methyl-2,6-dioxo-3,6-dihydro-2H-pyrimidine-1-yl]-1-phenylethylamino)butyric acid ethyl ester 
• 1092071-03-8 3-[(2R)-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-2,4(1H,3H)-pyrimidinedione trifluoroacetate 
• 830346-50-4 3-[(2R)-amino-2-phenylethyl]-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trifluoromethyl)benzyl]-6-methyl-2,4(1H,3H)-pyrimidinedione trifluoroacetate 

Relevant articles and documents

AN IMPROVED PROCESS FOR THE PREPARATION OF 4-({(1 R)-2-[5-(2-FLUORO-3METHOXYPHENYL)-3-{[2-FLUORO-6-(TRIFLUORO METHYL) PHENYL]METHYL}-4-METHYL-2,6-DIOXO-3,6DIHYDROPYRIMIDIN-1(2 H)-YL]-1-PHENYLETHYL}AMINO)BUTANOIC ACID OR ITS PHARMACEUTICALLY ACCEPTABLE SALTS

The present invention relates to an improved process for the preparation of 4- ({(1R) -2- [5- (2-fluoro- 3- methoxy phenyl) – 3 - {[ 2-fluoro- 6-(trifluoro methyl) phenyl] methyl} -4-methyl- 2,6-dioxo- 3,6-dihydropyrimidin-1(2H)-yl]-1-phenylethyl}amino) butanoic acid of formula (I) or its pharmaceutically acceptable salts. The compound of formula (I) is represented by the following structural formula.

Preparation method of oxragolian sodium

The invention provides a preparation method of oxagolide sodium. According to the method, the synthetic route of the oxogoliride sodium is improved, Boc protecting groups are removed by using concentrated hydrochloric acid, and then the oxogoliride sodium

AN IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX SODIUM

An improved process for the preparation of Elagolix Sodium having the structural formula (I). The present invention relates to highly pure compound of formula (VI) as a solid which is useful in the preparation of Elagolix sodium. The present invention pro

Substituted pyrimidine-2, 4(1H, 3H)-dione derivative and uses thereof

The invention belongs to the technical field of medicines, and relates to a substituted pyrimidine-2, 4(1H, 3H)-dione derivative and uses thereof, and a pharmaceutical composition containing the compound. The derivative and the pharmaceutical composition can be used as gonadotropin releasing hormone receptor antagonists. The invention also relates to a method for preparing the compound and the pharmaceutical composition, and uses of the compound and the pharmaceutical composition in prevention or treatment of sex hormone dependent diseases including but not limited to prostate cancer, endometriosis, hysteromyoma, precocious puberty and the like.

PROCESS FOR THE PREPARATION OF ELAGOLIX SODIUM AND INTERMEDIATES THEREOF

The present invention relates to compounds of Formula A, isomers, polymorphs and process of preparation thereof, wherein, S is a pharmaceutically acceptable salt, R is selected from hydrogen or C1-C3 alkyl group substituted with Rsu

Intermediate crystal form A of rotigotine and sodium salt thereof as well as preparation method and application thereof (by machine translation)

The invention discloses an intermediate crystal form A of and a sodium salt thereof, and a preparation method and application thereof, and relates to a medicine intermediate and a preparation method and application thereof. The preparation method provided

IMPROVED PROCESS FOR THE PREPARATION OF ELAGOLIX AND ITS INTERMEDIATES

The present invention provides an improved process for the preparation of Elagolix sodium of formula (I) and its intermediates. The present invention also provides a compounds of formula (V) and (VI), (X), (Xa) and (Xb). The present invention further prov

Preparation method of elagolix impurities

The invention relates to a synthetic method of three elagolix impurities which is important to the synthesis of high-quality elagolix. The invention mainly focuses on the study on a preparation methodof (R)-5-(2-fluoro-3-methoxyphenyl)-1-[2-fluoro-6-(trif

Preparation method of gonadotropin releasing hormone antagonist

The invention discloses a preparation method of a gonadotropin releasing hormone antagonist. According to the preparation method of the gonadotropin releasing hormone antagonist, a synthesis route ofNBI-56418 sodium is changed, an organic zinc reagent is used as a coupling reagent to perform a Negishi coupling reaction, conditions are mild and easy to control, few steps are performed, the reproducibility is good, the total yield is greatly improved, and the product purity is high and reaches more than 98.5%; and meanwhile, raw materials of the synthesis method are safe and low in cost and areenvironmentally friendly, and large-scale production is facilitated. If organic acid or mineral acid is added for activation during the preparation of the organic zinc reagent, the obtained organic zinc reagent can enable the activity of the Negishi coupling reaction to be higher, and the yield, the total yield and the product purity are further improved. According to the preparation method, hydrochloric acid is adopted to remove Boc, the cost is reduced, and side reactions can further be effectively reduced.

Preparation method of key intermediate of elagolix

The invention relates to the field of pharmacy, and concretely relates to a preparation method of a key intermediate of elagolix. The method adopts simple and easily available Boc-D-phenylglycinol asa starting material, and comprises the following steps: